SCHEMBL6489252

SCHEMBL6489252

COc1cc2c(cc1OC)CN(C(=O)/C=C/c1c(-c3ccc(F)cc3)n(C)c3ncccc13)CC2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.59
MEN1 O00255 4/20 0.59
ABCB1 P08183 5/20 0.58
MAPT P10636 2/20 0.49
ATM Q13315 1/20 0.47
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MDM2 Q00987 1/20 0.40
BCHE P06276 2/20 0.40
MAOA P21397 2/20 0.40
ACHE P22303 2/20 0.40
MAOB P27338 2/20 0.40
PDE4B Q07343 1/20 0.40
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2A P28223 1/20 0.39
SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489259 1.00 KMT2A (0.59) KMT2AMEN1ABCB1MAPTATM
Hydrochloric Acid SCHEMBL6479397 0.99 KMT2A (0.58) KMT2AMEN1ABCB1MAPTATM
Hydrochloric Acid SCHEMBL6479394 0.99 KMT2A (0.58) KMT2AMEN1ABCB1MAPTATM
SCHEMBL6478362 0.93 ABCB1 (0.58) KMT2AMEN1ABCB1MAPTATM
SCHEMBL6478356 0.93 ABCB1 (0.58) KMT2AMEN1ABCB1MAPTATM
SCHEMBL30655963 0.93 ABCB1 (0.66) KMT2AMEN1ABCB1MAPTATM
SCHEMBL6479525 0.93 ABCB1 (0.66) KMT2AMEN1ABCB1MAPTATM
SCHEMBL30680371 0.93 ABCB1 (0.66) KMT2AMEN1ABCB1MAPTATM
SCHEMBL6479530 0.93 ABCB1 (0.66) KMT2AMEN1ABCB1MAPTATM
SCHEMBL29382296 0.93 ABCB1 (0.66) KMT2AMEN1ABCB1MAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014942-A1 Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation NIPPON SHINYAKU CO., LTD. (JP) 2005-01-20 US claimed
EP-1452525-A1 AMIDE DERIVATIVES AND DRUGS Nippon Shinyaku Co., Ltd. (JP) 2004-09-01 EP claimed
US-20050014942-A1 Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation NIPPON SHINYAKU CO., LTD. (JP) 2005-01-20 US disclosed
EP-1452525-A1 AMIDE DERIVATIVES AND DRUGS Nippon Shinyaku Co., Ltd. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014942-A1 Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation TGFBR1, TGFBR2, TGFB1 KMT2A 1575/4885MEN1 1774/4885ABCB1 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.